ABN Amro Investment Solutions Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

ABN Amro Investment Solutions acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 130,291 shares of the pharmaceutical company’s stock, valued at approximately $58,006,000. Vertex Pharmaceuticals makes up approximately 1.2% of ABN Amro Investment Solutions’ portfolio, making the stock its 24th biggest holding. ABN Amro Investment Solutions owned about 0.05% of Vertex Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. United Services Automobile Association bought a new stake in Vertex Pharmaceuticals during the 1st quarter worth about $2,933,000. Lee Johnson Capital Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $721,000. Bailard Inc. grew its position in shares of Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after buying an additional 200 shares during the period. SteelPeak Wealth LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $10,059,000. Finally, Moody Lynn & Lieberson LLC lifted its holdings in Vertex Pharmaceuticals by 1.4% in the second quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock valued at $25,856,000 after buying an additional 822 shares during the period. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. Royal Bank Of Canada decreased their price objective on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 4th. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price objective for the company in a report on Wednesday, August 6th. Finally, Scotiabank reduced their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $489.10.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $434.19 on Thursday. The business has a 50 day simple moving average of $406.47 and a 200 day simple moving average of $428.20. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68. The stock has a market cap of $110.16 billion, a price-to-earnings ratio of 31.04 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the firm posted $4.38 earnings per share. The business’s revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.